SEC Form 4 · accession 0001209191-18-011244
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Feb 16, 2018
Accepted (ET)
Feb 20, 2018 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Feb 16, 2018 | M | 2,000 | $35.16 | A | 2,881 | D | |
| Common stockF3 | Feb 16, 2018 | S | 1,500 | $77.51 | D | 1,381 | D | |
| Common stockF4 | Feb 16, 2018 | S | 500 | $78.08 | D | 881 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F5 | $35.16 | Feb 16, 2018 | M | 2,000 | D | — | May 30, 2024 | Common stock | 2,000 | 105,000 | D |
| Stock option (right to buy)F6 | $77.70 | Feb 16, 2018 | A | 33,000 | A | — | Feb 15, 2028 | Common stock | 33,000 | 33,000 | D |
| Restricted stock unitsF7,F8 | — | Feb 16, 2018 | A | 8,250 | A | — | — | Common stock | 8,250 | 8,250 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.98 to $77.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.00 to $78.21. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F6This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F7Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F8The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested.